EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...
with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia 1, disorders characterized by very low or absent levels of antibodies and an increased risk of ...
The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback